Emitted dose estimates from Seretide® Diskus® and Symbicort® Turbuhaler® following inhalation by severe asthmatics
No === The dose emitted from dry powder inhalers may be inhalation flow-dependent. Using an ex vivo method, the Electronic Lung¿, we have measured the aerodynamic characteristics of the emitted dose for both active constituents from Seretide® Diskus® (salmeterol xinafoate 50 mcg; fluticasone propion...
Main Authors: | , , , |
---|---|
Language: | en |
Published: |
2009
|
Subjects: | |
Online Access: | http://hdl.handle.net/10454/4128 |
id |
ndltd-BRADFORD-oai-bradscholars.brad.ac.uk-10454-4128 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-BRADFORD-oai-bradscholars.brad.ac.uk-10454-41282019-08-31T03:02:01Z Emitted dose estimates from Seretide® Diskus® and Symbicort® Turbuhaler® following inhalation by severe asthmatics Assi, Khaled H. Chrystyn, Henry Pearson, S.B. Tarsin, W. Diskus® Turbuhaler® Electronic Lung¿ Dose Asthma No The dose emitted from dry powder inhalers may be inhalation flow-dependent. Using an ex vivo method, the Electronic Lung¿, we have measured the aerodynamic characteristics of the emitted dose for both active constituents from Seretide® Diskus® (salmeterol xinafoate 50 mcg; fluticasone propionate 500 mcg) and Symbicort® Turbuhaler® (formoterol 6 mcg; budesonide 200 mcg).1 Electronic inhalation profiles were collected from 20 severe asthmatics (mean PEFR 53% predicted) when they inhaled using a placebo Seretide® Diskus® and a placebo Symbicort® Turbuhaler®. These were replayed in the Electronic Lung¿ with the respective active inhaler in situ. Mean(S.D.) peak inhalation flow rates (PIFR) through the Diskus® and Turbuhaler® were 94.7(32.9) and 76.8(26.2) l min¿1, respectively. From the Electronic Lung¿ the Diskus® inhalation profiles provided a mean(S.D.) fine particle dose (FPD) for fluticasone propionate and salmeterol of 20.4(4.8) and 18.4(4.4)% labelled dose. For Turbuhaler® inhalation profiles the FPD was 23.1(12.9) and 20.7(11.1)% labelled dose for budesonide and formoterol, respectively. The linear (p < 0.001) relationships between FPD against PIFR for budesonide and formoterol were 3 (p = 0.002) and 2.8 (p = 0.007) times steeper than fluticasone propionate and salmeterol, respectively. The results highlight a more significant effect of inspiratory flow on variable dosage emission when using the Symbicort® Turbuhaler® compared with the Seretide® Diskus®. 2009-12-17T13:49:41Z 2009-12-17T13:49:41Z 2006 Article No full-text available in the repository Assi, K.H., Chrystyn, H., Pearson, S.B. and Tarsin, W. (2006). Emitted dose estimates from Seretide® Diskus® and Symbicort® Turbuhaler® following inhalation by severe asthmatics. International Journal of Pharmaceutics. Vol. 316, No. 1-2, pp. 131-137. http://hdl.handle.net/10454/4128 en http://dx.doi.org/10.1016/j.ijpharm.2006.02.040 |
collection |
NDLTD |
language |
en |
sources |
NDLTD |
topic |
Diskus® Turbuhaler® Electronic Lung¿ Dose Asthma |
spellingShingle |
Diskus® Turbuhaler® Electronic Lung¿ Dose Asthma Assi, Khaled H. Chrystyn, Henry Pearson, S.B. Tarsin, W. Emitted dose estimates from Seretide® Diskus® and Symbicort® Turbuhaler® following inhalation by severe asthmatics |
description |
No === The dose emitted from dry powder inhalers may be inhalation flow-dependent. Using an ex vivo method, the Electronic Lung¿, we have measured the aerodynamic characteristics of the emitted dose for both active constituents from Seretide® Diskus® (salmeterol xinafoate 50 mcg; fluticasone propionate 500 mcg) and Symbicort® Turbuhaler® (formoterol 6 mcg; budesonide 200 mcg).1 Electronic inhalation profiles were collected from 20 severe asthmatics (mean PEFR 53% predicted) when they inhaled using a placebo Seretide® Diskus® and a placebo Symbicort® Turbuhaler®. These were replayed in the Electronic Lung¿ with the respective active inhaler in situ. Mean(S.D.) peak inhalation flow rates (PIFR) through the Diskus® and Turbuhaler® were 94.7(32.9) and 76.8(26.2) l min¿1, respectively. From the Electronic Lung¿ the Diskus® inhalation profiles provided a mean(S.D.) fine particle dose (FPD) for fluticasone propionate and salmeterol of 20.4(4.8) and 18.4(4.4)% labelled dose. For Turbuhaler® inhalation profiles the FPD was 23.1(12.9) and 20.7(11.1)% labelled dose for budesonide and formoterol, respectively. The linear (p < 0.001) relationships between FPD against PIFR for budesonide and formoterol were 3 (p = 0.002) and 2.8 (p = 0.007) times steeper than fluticasone propionate and salmeterol, respectively. The results highlight a more significant effect of inspiratory flow on variable dosage emission when using the Symbicort® Turbuhaler® compared with the Seretide® Diskus®. |
author |
Assi, Khaled H. Chrystyn, Henry Pearson, S.B. Tarsin, W. |
author_facet |
Assi, Khaled H. Chrystyn, Henry Pearson, S.B. Tarsin, W. |
author_sort |
Assi, Khaled H. |
title |
Emitted dose estimates from Seretide® Diskus® and Symbicort® Turbuhaler® following inhalation by severe asthmatics |
title_short |
Emitted dose estimates from Seretide® Diskus® and Symbicort® Turbuhaler® following inhalation by severe asthmatics |
title_full |
Emitted dose estimates from Seretide® Diskus® and Symbicort® Turbuhaler® following inhalation by severe asthmatics |
title_fullStr |
Emitted dose estimates from Seretide® Diskus® and Symbicort® Turbuhaler® following inhalation by severe asthmatics |
title_full_unstemmed |
Emitted dose estimates from Seretide® Diskus® and Symbicort® Turbuhaler® following inhalation by severe asthmatics |
title_sort |
emitted dose estimates from seretide® diskus® and symbicort® turbuhaler® following inhalation by severe asthmatics |
publishDate |
2009 |
url |
http://hdl.handle.net/10454/4128 |
work_keys_str_mv |
AT assikhaledh emitteddoseestimatesfromseretidediskusandsymbicortturbuhalerfollowinginhalationbysevereasthmatics AT chrystynhenry emitteddoseestimatesfromseretidediskusandsymbicortturbuhalerfollowinginhalationbysevereasthmatics AT pearsonsb emitteddoseestimatesfromseretidediskusandsymbicortturbuhalerfollowinginhalationbysevereasthmatics AT tarsinw emitteddoseestimatesfromseretidediskusandsymbicortturbuhalerfollowinginhalationbysevereasthmatics |
_version_ |
1719238949829869568 |